Collectively, these findings show that 3xTg-AD mice have increased resting and fasted glucose levels, that their response to insulin and glucose challenge is moderately affected in mid-life, and that these metabolic features are not modulated by 1-month central administration of SCDi. Here, INS is linked to Alzheimer disease.